Prevalence of Regulatory Safety Risk Factors Among Adolescents and Adults With Atopic Dermatitis Receiving Advanced Systemic Therapies
An International Real-World Study.
Alvarenga JM, Yeung J, Prajapati V, Ribero S, Balato A, Marzano AV, Cruz MJ, Lopes MJP, Lazaridou E, Carrascosa JM, Farinha P, Duarte B, Sood S, Rankin BD, Ortoncelli M, Caccavale S, Ferrucci SM, Rosa GP, Daponte AI, Silvi G, Peris K, Gori N, Herranz P, Prignano F, Kolios AGA, Rompoti N, Gregoriou S, Gkalpakiotis S, Chiricozzi A, Torres T
International Journal of DermatologyIn the feed 5 Aug 2026, published online 4 Aug 2026, issue 2026 Aug 04, added to PubMed 5 Aug 2026
Topics: Atopic dermatitis & eczemaChildrenBiologicsJAK inhibitors & other targeted pills
Abstract
PubMed has no abstract for this paper, as is usual for research letters, correspondence and editorials. The publisher’s page has the full paper.
PMID 42552629 · DOI 10.1111/ijd.70617